Commercialization and Marketing Sample Clauses
Commercialization and Marketing. 5.1 Commercialization of the Licensed Product.
Commercialization and Marketing. 5.1 At least one (1) year prior to the expected date of the receipt by IMPH (or its Sub-sublicensee) of the first Marketing Approval for use in the Licensed Field, as indicated in then-current Development Plan, IMPH shall create and provide to iCo a written summary plan showing a reasonably-detailed summary of the commercialization and marketing efforts with respect to the relevant Licensed Product in the Licensed Field in the Territory (the “Commercialization Plan”). IMPH (or its Sub-sublicensee, as applicable) shall have the right to amend, supplement and/or update the Commercialization Plan from time to time as needed or commercially appropriate, and IMPH shall provide to iCo promptly a copy of each such amended, supplemented or updated Commercialization Plan.
5.2 IMPH shall have the exclusive rights and responsibility to conduct all Commercialization and marketing activities with respect to Licensed Products for use in the Licensed Field, generally in accordance with the then-current Commercialization Plan, whether through itself and/or its Sub-sublicensees. IMPH shall use Reasonable Endeavors to market, promote, sell and otherwise Commercialize Licensed Products for use in the Licensed Field in each country in the Territory where Licensed Product has achieved Marketing Approval, with the goal of maximizing sales of such Licensed Products.
5.3 IMPH (and/or its Sub-sublicensees, as applicable) will be responsible from the Effective Date for all costs associated with the Commercialization and marketing of the Licensed Products in the Licensed Field and for all regulatory filings and other regulatory activities by IMPH (and its Sub-sublicensees, as applicable) in the Territory. Portions of this Exhibit, indicated by the xxxx “[***]”, were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Exchange Act of 1934, as amended. Portions marked by * were summarized]
5.4 To the extent not prohibited by Applicable Law and subject to Competent Authority and regulatory approval, and if requested by iCo to IMPH in writing, the iCo company chosen name and company logo (or one specified by CAT, as applicable) shall be carried on Licensed Product packaging, packaging inserts, labels, containers and printed material related thereto, with a prominence as mutually agreed to by iCo and IMPH (such agreement not to be unreasonably withheld b...
Commercialization and Marketing. (a) Vivitech agrees to undertake all expenses of developing and commercializing the Product, including (but not limited to) funding capital equipment requirements, packaging, and other production start-up expenses.
(b) Vivitech shall obtain Hologic's prior approval of each use of Hologic's name, trademarks, or service marks and, to such end, shall submit a prototype of each such use to Hologic for review. Hologic's approval of such uses shall not be unreasonably withheld. Hologic shall be deemed to have approved a proposed use of its name, trademarks, or service marks if it has not objected thereto in writing within ten (10) days following its receipt of the prototype therefor.
Commercialization and Marketing. Notwithstanding ------------------------------- anything in the Agreement to the contrary, effective as of the ORTHO Suspension Date, ORTHO shall have no obligations for Commercialization or Marketing under the Agreement until the ORTHO Resumption Date.
Commercialization and Marketing. LICENSEE shall use reasonably diligent efforts to promote the sales of the Products, it being understood that reasonably diligent efforts to promote the sales shall mean that LICENSEE shall offer materially similar commissions and marketing programs for the Products as it offers for similar products.
Commercialization and Marketing. 3.1 COMMERCIALIZATION DILIGENCE. IPR will file its application for FDA approval to market the Product in the United States and [...***...] (such countries together with the United States hereafter called "Major Countries") within [...***...] of final stability data for the Product being available to IPR. Such filing timetable is based upon the following assumptions: that regulatory authorities will approve the Product on the basis of a successful bioequivalence study only, and that an efficacy study is not required; and that the following stability data will be sufficient for regulatory approval: [...***...] [...***...] [...***...] ------------------- *CONFIDENTIAL TREATMENT REQUESTED 1 If either clinical efficacy data or additional stability data is required, IPR's filing timetable will be amended to be not more than [...***...] after the last required data becomes available to IPR. IPR will launch the Product in each Major Country in which it receives regulatory and pricing approval to market the Product within [...***...] of receiving the later received approval.
Commercialization and Marketing. Licensee shall undertake all expenses of commercializing the Licensed Products in the Territory, including funding capital requirements, packaging, and production expenses.
Commercialization and Marketing.
4.1 Commercialization of the Licensed Product in the Territory. Unless explicitly provided for differently elsewhere in this Agreement, Lian shall have sole control over and decision-making authority with respect to the Commercialization of the Licensed Product in the Field in the Territory, including marketing, strategy, pricing, promotion, physician targeting, reimbursement, branding, distribution, and sales. All costs and expenses of Commercialization, including for distribution, marketing and selling, of the Licensed Product in the Field in the Territory shall be for Lian’s account.
Commercialization and Marketing. 5.1 GRANT OF RIGHTS Xenova hereby grants to QLT the exclusive right and QLT shall have the responsibility, at QLT's cost, for the commercialization, marketing and sale of the Drug and/or the Product in the Field in the Territory, on and subject to the terms and conditions set out in this Agreement (including Section 8.4).
Commercialization and Marketing